1 |
Saniabadi AR, Tanaka T, Ohmori T, Sawada K, Yamamoto T, Hanai H. Treating inflammatory bowel disease by adsorptive leucocytapheresis: A desire to treat without drugs. World J Gastroenterol 2014; 20(29): 9699-9715 [PMID: 25110409 DOI: 10.3748/wjg.v20.i29.9699] [Cited by in CrossRef: 54] [Cited by in F6Publishing: 57] [Article Influence: 6.0] [Reference Citation Analysis]
|
2 |
Sigurbjörnsson FT, Bjarnason I. Leukocytapheresis for the treatment of IBD. Nat Clin Pract Gastroenterol Hepatol. 2008;5:509-516. [PMID: 18665138 DOI: 10.1038/ncpgasthep1209] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 0.8] [Reference Citation Analysis]
|
3 |
Pineda AA. Developments in the apheresis procedure for the treatment of inflammatory bowel disease. Inflamm Bowel Dis 2006;12 Suppl 1:S10-4. [PMID: 16378005 DOI: 10.1097/01.mib.0000195386.19268.b3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 0.8] [Reference Citation Analysis]
|
4 |
Saniabadi AR, Hanai H, Suzuki Y, Ohmori T, Sawada K, Yoshimura N, Saito Y, Takeda Y, Umemura K, Kondo K, Ikeda Y, Fukunaga K, Nakashima M, Beretta A, Bjarnason I, Lofberg R. Adacolumn for selective leukocytapheresis as a non-pharmacological treatment for patients with disorders of the immune system: an adjunct or an alternative to drug therapy? J Clin Apher. 2005;20:171-184. [PMID: 15892107 DOI: 10.1002/jca.20046] [Cited by in Crossref: 78] [Cited by in F6Publishing: 86] [Article Influence: 4.3] [Reference Citation Analysis]
|
5 |
Gaubitz M, Schneider KM. Immunoadsorption in systemic lupus erythematosus: different techniques and their current role in medical therapy. Ther Apher Dial 2003;7:183-8. [PMID: 12918941 DOI: 10.1046/j.1526-0968.2003.00040.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 0.7] [Reference Citation Analysis]
|
6 |
Saniabadi AR, Hanai H, Takeuchi K, Umemura K, Nakashima M, Adachi T, Shima C, Bjarnason I, Lofberg R. Adacolumn, an adsorptive carrier based granulocyte and monocyte apheresis device for the treatment of inflammatory and refractory diseases associated with leukocytes. Ther Apher Dial 2003;7:48-59. [PMID: 12921115 DOI: 10.1046/j.1526-0968.2003.00012.x] [Cited by in Crossref: 198] [Cited by in F6Publishing: 209] [Article Influence: 9.9] [Reference Citation Analysis]
|
7 |
Schneider M. Plasmapherese und Zytapherese. Interdisziplinäre klinische Rheumatologie 2001. [DOI: 10.1007/978-3-662-07967-6_25] [Reference Citation Analysis]
|
8 |
Illei GG, Klippel JH. Apheresis. Rheum Dis Clin North Am 2000;26:63-73, viii. [PMID: 10680194 DOI: 10.1016/s0889-857x(05)70120-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.1] [Reference Citation Analysis]
|
9 |
Schneider M, Gaubitz M, Perniok A. Immunoadsorption in systemic connective tissue diseases and primary vasculitis. Ther Apher 1997;1:117-20. [PMID: 10225754 DOI: 10.1111/j.1744-9987.1997.tb00024.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 0.5] [Reference Citation Analysis]
|